Business Wire

Experian Brings Trusted Agentic AI to Financial Services With the Launch of Agent Operating System™

2.6.2026 15:05:00 CEST | Business Wire | Press Release

Share

Experian today announces the launch of the Agent Operating System™, a trusted agentic AI layer within the Experian Ascend Platform, unveiled at Money20/20 Europe.

The Experian Agent Operating System is designed to help financial services organisations move successfully beyond AI experimentation and safely scale agentic AI to transform decision-making, customer experiences, and day-to-day operations. It enables AI agents from Experian, clients and partners to work together through a common trust, semantic and orchestration layer, supported by clear controls, auditability and human oversight.

The launch comes as financial services firms accelerate investment in AI but continue to face major barriers to scaling adoption. New Experian research* shows that nearly half of global organisations (48%), say integrating data into AI workflows remains difficult, while a third cite poor data lineage and a further third say data is siloed across teams and systems.

At the same time, consumers are increasingly open to AI acting on their behalf, with 55%** willing to use AI tools for online purchases or bookings, rising to 70% among 25-39-year-olds.

Vijay Mehta, General Manager AI, Experian Software Solutions, said: “Agentic AI will reshape financial services, changing how decisions are made, how customers are served and how organisations operate at scale. This is no longer about experimentation. The winners will be those who turn AI into trusted operational reality, built on high quality data, strong governance and transparency in every decision.

“The Experian Agent Operating System is built for that moment. It brings together our unique data, advanced analytics, decisioning expertise and embedded governance within the Ascend Platform to help organisations deploy AI with confidence. This ultimately enables clients to automate key lending workflows, like fraud checks or loan approvals, in real time compared to the fragmented manual processes many rely on today.”

ServiceNow, the AI control tower for business reinvention, will be the first partner to integrate with Experian’s Agent Operating System. Through the multi-year partnership, ServiceNow AI agents will connect with Experian’s Ascend Platform, allowing customers to access trusted data, decisioning and governance capabilities within existing enterprise workflows.

Cedric Parent, GVP, Global Industries at ServiceNow, said: “Financial services firms are under enormous pressure, with tightening regulations, rising fraud complexity, and rising customers’ expectations. The ambition to deploy agentic AI is there, but without access to trusted, real-time data inside enterprise workflows, agents simply can't operate at the speed or scale the industry demands. ServiceNow is proud to be the first partner deploying within Experian's Agent Operating System, giving financial institutions the confidence to automate high-stakes decisions, from fraud detection to credit risk."

Supporting the full lending lifecycle from customer acquisition and fraud detection to credit decisioning, portfolio monitoring, and reporting, Agent Operating System bridges the gap between AI ambition and operational reality. It combines data, analytics, decisioning, and identity with built-in governance, risk management, explainability, and controls to enable trusted complex workflow automation.

The Agent Operating System will be available to early adopters later this year, before rolling out to more than 2,300 client solutions globally. Key capabilities include:

  • A trusted agentic operating layer: Identity, access control, data security, compliance guardrails, monitoring and governance controls that enable AI agents to operate safely across data, models and workflows.
  • Composability: Experian, client-built, and partner agents work together without having to replace existing technology, allowing organisations to start with targeted use cases and progressively evolve toward fully connected, agent-driven workflows.
  • Agent-native decisioning: Purpose-built agents across fraud, identity, credit risk, marketing, analytics, operations and governance that can investigate, orchestrate and optimise workflows, rather than simply respond to prompts.
  • Embedded governance by design: Model risk management, explainability, audit trails, monitoring and policy enforcement built into agentic workflows to support compliant AI at enterprise scale.
  • Productivity at scale, with human oversight: Automation of investigation, strategy execution, insight generation, documentation and monitoring, with human-in-the-loop validation for complex decisions and high-impact outcomes.

Experian is a 5-star sponsor of Money20/20 Europe in Amsterdam and will host the event’s Connection Lounge. Adolfo Tunon, Head of Banking GTM, EMEA at ServiceNow will join Experian’s Vijay Mehta and Laurie Schnidman on stage to discuss the launch of Agent Operating System and the future of agentic AI in financial services.

Learn more about the Connected Intelligence report here, and the 2026 UK Fraud and FinCrime Report 2026 here.

Notes to Editor:

*Experian and Phronesis conducted a global survey in April and May 2026 among more than 800 senior decision-makers at financial institutions across the United States, United Kingdom, Brazil, Australia, New Zealand, Spain, Germany, India, Italy, South Africa, Colombia, and Chile.

**Research conducted by HarrisX between March and April 2026 among more than 500 senior decision-makers at organisations across the UK.

About Experian

Experian is a global data and technology company, powering opportunities for people and businesses around the world. We help to redefine lending practices, uncover and prevent fraud, simplify healthcare, deliver digital marketing solutions, and gain deeper insights into the automotive market, all using our unique combination of data, analytics and platforms. We also assist millions of people to realise their financial goals and help them to save time and money.

We operate across a range of markets, from financial services to healthcare, automotive, agrifinance, insurance, and many more industry segments.

We invest in talented people and new advanced technologies to unlock the power of data and to innovate. A FTSE 100 Index company listed on the London Stock Exchange (EXPN), we have a team of 25,200 people across 33 countries. Our corporate headquarters are in Dublin, Ireland. Learn more at experianplc.com.

© 2026 ServiceNow, Inc. All rights reserved. ServiceNow, the ServiceNow logo, Now, and other ServiceNow marks are trademarks and/or registered trademarks of ServiceNow, Inc. in the United States and/or other countries. Other company names, product names, and logos may be trademarks of the respective companies with which they are associated.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260602784773/en/

Contacts

Media contact:
Robert Goodman, PR Manager, Corporate & Business, UK&I, Experian
Tel: +44 7989 398 498 / Email: Robert.Goodman@Experian.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press Release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press Release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye